[{"symbol": "INSM", "price": 161.42, "beta": 1.087, "volAvg": 3050361, "mktCap": 34426603366, "lastDiv": 0, "range": "60.4-212.75", "changes": 2.15, "companyName": "Insmed Incorporated", "currency": "USD", "cik": "0001104506", "isin": "US4576693075", "cusip": "457669307", "exchange": "NASDAQ Global Select", "exchangeShortName": "NASDAQ", "industry": "Medical - Pharmaceuticals", "website": "https://www.insmed.com", "description": "Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.", "ceo": "William H. Lewis", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "1271", "phone": "908 977 9900", "address": "700 US Highway 202/206", "city": "Bridgewater", "state": "NJ", "zip": "08807", "dcfDiff": 244.0699, "dcf": -82.64990017089822, "image": "https://images.financialmodelingprep.com/symbol/INSM.png", "ipoDate": "2000-06-01", "defaultImage": false, "isEtf": false, "isActivelyTrading": true, "isAdr": false, "isFund": false}]